Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
RVMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$29.17 - $62.40
Previous CloseN/A
Volume180.68K
Average Volume (3M)1.71M
Market Cap
$7.17B
Enterprise Value$6.10B
Total Cash (Recent Filing)$543.06M
Total Debt (Recent Filing)$135.84M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
May 12, 2025EPS Estimate
-1.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.57
Shares Outstanding185,913,330
10 Day Avg. Volume1,858,942
30 Day Avg. Volume1,713,234
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)12629.51
Price to Cash Flow (P/CF)-12.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.94
Forecast
1Y Price Target
$68.30Price Target Upside77.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Revolution Medicines News
PremiumCompany Announcements
Revolution Medicines’ Earnings Call: Positive Progress Amid Rising Costs
PremiumCompany Announcements
Revolution Medicines Reports 2024 Financial Results and Progress
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentRevolution Medicine's lead asset, daraxonrasib, is in Phase 3 for adjuvant, 1L, and 2L PDAC and 2L NSCLC, indicating significant progress in its clinical development.
Financial PositionRevolution ended 2024 with roughly $2.29B in cash and cash equivalents, providing an operational runway through multiple key data catalysts.
Market PotentialDaraxonrasib is seen as an emerging multi-billion dollar drug and RVMD remains a top performer.
Bears Say
Financial PerformanceRVMD reported a net loss of $194.5M, or ($1.12)/share, higher than expected due to more than expected operating expenses.
Regulatory And Clinical RisksRisks include clinical setbacks, inability to secure timely regulatory approval, and potential long-term dilution risk.
---
Ownership Overview
6.44% Insiders
25.80% Mutual Funds
0.05% Other Institutional Investors
51.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RVMD FAQ
What was Revolution Medicines’s price range in the past 12 months?
Revolution Medicines lowest stock price was $29.17 and its highest was $62.40 in the past 12 months.
What is Revolution Medicines’s market cap?
Revolution Medicines’s market cap is $7.17B.
When is Revolution Medicines’s upcoming earnings report date?
Revolution Medicines’s upcoming earnings report date is May 12, 2025 which is in 16 days.
How were Revolution Medicines’s earnings last quarter?
Revolution Medicines released its earnings results on Feb 26, 2025. The company reported -$1.12 earnings per share for the quarter, missing the consensus estimate of -$0.986 by -$0.134.
Is Revolution Medicines overvalued?
According to Wall Street analysts Revolution Medicines’s price is currently Undervalued.
Does Revolution Medicines pay dividends?
Revolution Medicines does not currently pay dividends.
What is Revolution Medicines’s EPS estimate?
Revolution Medicines’s EPS estimate is -1.1.
How many shares outstanding does Revolution Medicines have?
Revolution Medicines has 185,913,330 shares outstanding.
What happened to Revolution Medicines’s price movement after its last earnings report?
Revolution Medicines reported an EPS of -$1.12 in its last earnings report, missing expectations of -$0.986. Following the earnings report the stock price went down -3.506%.
Which hedge fund is a major shareholder of Revolution Medicines?
Currently, no hedge funds are holding shares in RVMD
---
Revolution Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$68.30 (77.03% Upside)
$68.30 (77.03% Upside)
Blogger Sentiment
Neutral
RVMD Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $60.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 12.7%
Last 30 Days ▼ 12.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.40%
12-Months-Change
Fundamentals
Return on Equity
-29.33%
Trailing 12-Months
Asset Growth
24.65%
Trailing 12-Months
Company Description
Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
---
RVMD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in Revolution Medicines' RAS(ON) inhibitor pipeline and a strong financial position to support future operations. However, increased net losses and operating expenses were noted. The overall sentiment leans positive given the advancements in clinical trials and strategic collaborations.Read More>---
RVMD Stock 12 Month Forecast
Average Price Target
$68.30
▲(77.03% Upside)
Technical Analysis
Teleflex
―
The Ensign Group
―
Blueprint Medicines
―
BridgeBio Pharma
―
Roivant Sciences
―
Best Analysts Covering RVMD
1 Year
1 Year Success Rate
10/16 ratings generated profit
1 Year Average Return
+14.91%
reiterated a buy rating 26 days ago
Copying Benjamin Burnett's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +14.91% per trade.
---